Humacyte's Phase 3 Trial Data for Dialysis Access Set for ASN Kidney Week Debut

  • Interim Phase 3 V012 trial results for ATEV in female hemodialysis patients accepted for late-breaking oral session at ASN Kidney Week 2026.
  • Trial compares Humacyte's acellular tissue engineered vessel (ATEV) with autogenous arteriovenous fistula (AVF) in end-stage kidney disease patients.
  • Supplemental BLA for AV access in hemodialysis targeted for FDA submission this quarter.
  • Presentation scheduled for October 22, 2026, in Denver, Colorado.

Humacyte's presentation at ASN Kidney Week underscores the strategic importance of addressing unmet needs in hemodialysis access, particularly for female patients who face higher fistula failure rates. The pending supplemental BLA submission reflects the company's push to expand its Symvess® label, positioning it as a key player in the vascular access market. Success in this area could drive significant revenue growth and solidify Humacyte's leadership in bioengineered human tissues.

Regulatory Momentum
Whether the Phase 3 data will support a successful supplemental BLA submission and expedite FDA approval for expanded AV access indications.
Market Differentiation
How the ATEV's performance in female patients compares to existing dialysis access solutions, potentially expanding its market reach.
Commercial Strategy
The pace at which Humacyte can scale manufacturing and distribution to meet anticipated demand if regulatory approvals are achieved.